LOGIN  |  REGISTER
Chimerix

Veeva Systems to Present at Upcoming Investor Conference

January 16, 2024 | Last Trade: US$215.95 4.71 -2.13

PLEASANTON, Calif., Jan. 16, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced participation in the following virtual investor conference:

  • 26th Annual Needham Growth Conference. Brent Bowman, CFO, and Paul Shawah, EVP Commercial Strategy, are presenting on Friday, January 19, 2024, at 10:15 a.m. Eastern Time.

The presentation will be webcast. Links to the live and archived webcast will be available on Veeva's investor relations website at https://ir.veeva.com.

About Veeva Systems

Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.

Veeva uses its ir.veeva.com website as a means of disclosing material non-public information, announcing upcoming investor conferences, and for complying with its disclosure obligations under Regulation FD. Accordingly, you should monitor Veeva's investor relations website in addition to following its press releases, SEC filings, and public conference calls and webcasts.

Investor Relations Contact: 
Gunnar Hansen
Veeva Systems Inc. 
267-460-5839
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Media Contact:
Maria Scurry
Veeva Systems Inc.
781-366-7617
This email address is being protected from spambots. You need JavaScript enabled to view it. 

C4 Therapeutics

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page